Immunexpress Appoints Dr. Roy Davis Chief Medical Officer

SEATTLE, Oct. 22, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the appointment of Roy F. J. Davis, Ph.D., M.D., M.H.A., as Chief Medical Officer.

"Dr. Davis has over 30 years of experience providing and directing patient care for multiple healthcare-provider organizations," said Roslyn Brandon, President and CEO of Immunexpress. "His wealth of knowledge in the implementation of the sepsis surveillance programs will prove extraordinarily useful as we advance our molecular diagnostic test for sepsis toward clearance by the FDA."

Dr. Davis previously served from 2002 through 2013 as Chief Medical Officer of Providence Health and Services' Alaska region where he assisted in the implementation of the modified early warning system (MEWS) and sepsis surveillance algorithms using the Microsoft Amalga platform. Dr. Davis was named the Microsoft Investigator of the Year for his work with MEWS in 2012. From 1986 to 1998, he was a Clinical Assistant Professor with the WAMI program in the Department of Pediatrics at the University of Washington.

Dr. Davis holds a medical degree and a clinical chemistry from the Medical College of Virginia and completed his internship and residency in pediatrics at the University of Washington Children's Hospital. Dr. Davis also holds an M.H.A. from the University of Colorado School of Business.

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system the "host response." Detecting the host's septic immune response can diagnose sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. For more information visit

Follow Immunexpress on Twitter at and LinkedIn at

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

To view the original version on PR Newswire, visit:

SOURCE Immunexpress, Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.